According to the Centers for Disease Control (CDC), depression affects 1 in 10 Americans at one point or another, and is most prevalent in people ages 45 to 64. The number of patients diagnosed with depression increases by approximately 20% every year, and states with higher rates of depression also have high rates of obesity, heart disease, stroke, and sleep disorders. An estimated 80% of individuals affected by depression do not receive any treatment, and many of them don’t seek treatment because they haven’t been diagnosed as having depression.
Depression is a mood disorder that causes a persistent feeling of sadness or loss of interest. It is an extremely complex disease caused by a variety of factors in a person’s life. Factors that increase the chance of depression include genetics, certain medications, abuse, conflict, the death of a loved one, or the loss of a job.
Now, there’s a genetic test called the The Genecept Assay from Genomind which aids in the treatment of not only depression, but also post-traumatic stress disorder (PTSD), anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, autism and schizophrenia.
Since mental disorders, such as depression, take on many forms and are caused by a number of factors, prognosis and treatment are often difficult to determine. Furthermore, every person responds to medication differently. Five individuals with the same mental symptoms could react to the same medication in five different ways. When you factor in the risk of prescribing the wrong dosage, the process of treating patients with mental disorders becomes a trial-and-error guessing game, which could be risky and dangerous.
With the advent of the Genecept Assay Test, psychiatrists no longer have to play a guessing game when it comes to the health of their patients. The test entails collecting a saliva sample from a patient via a cheek swab. A certified lab performs the genetic testing focusing on neurotransmitter and metabolism pathways. Based on the markers, a clinician interprets the results, diagnoses the condition, and is able to determine treatment and medication regimens that will have the most effective and positive outcome for an individual patient.
In other words, the test takes the guesswork out of diagnosing and treating mental disorders. The test has proven so useful that the General Services Administration has approved it for veterans and active military personnel, who are now eligible to receive the Genecept Assay Test, which helps them feel better faster. It’s a game-changing breakthrough that may revolutionize the mental health industry forever.
The cost of the test is still quite prohibitive—approximately $800—which renders it unaffordable to the average person. But such a cost may be justifiable for individuals who have been suffering for long and want return to a normal life or equilibrium; those whose quality of life (or will to live) depends on effective treatment; and especially those individuals who are prone to destructive behavior or are at risk for suicide. For more information, visit GenoMind’s website at https://genomind.com.